Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.52 |
| ▸ | CTSK | P43235 | 7/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | HRH2 | P25021 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338649 | 0.89 | ACE (0.62) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL16658 | 0.89 | ACE (0.62) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL478774 | 0.89 | ACE (0.62) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL13541200 | 0.88 | KLK5 (0.57) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL3364787 | 0.88 | KLK5 (0.57) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL13538229 | 0.88 | KLK5 (0.57) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL17452269 | 0.87 | CTSS (0.48) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6752505 | 0.86 | ACE (0.54) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL7328199 | 0.86 | CTSS (0.56) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL9491980 | 0.86 | CTSS (0.56) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699895-B2 | CYCLIZING THE TERT-BUTYL-THIOUREA DERIVATIVE TO FORM THE END PRODUCT | AVENTIS PHARMA S.A. (FR) | 2004-03-02 | — | — | US | disclosed |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | CTSS 3866/4885CTSK 4438/4885CTSB 4701/4885 |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | NOS3, TH, CBR1 | CTSS 3131/4885CTSK 4019/4885CTSB 4513/4885 |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | NOS2, NOS3, NOS1 | CTSS 3867/4885CTSK 4466/4885CTSB 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.